Advanced Therapy Medicinal Products CDMO Market Overview:
As per MRFR analysis, the advanced therapy medicinal products CDMO market Size was estimated at 19.89 (USD Billion) in 2022. The advanced therapy medicinal products CDMO market is expected to grow from 22.8 (USD Billion) in 2023 to 78.0 (USD Billion) by 2032. The advanced therapy medicinal products CDMO market CAGR (growth rate) is expected to be around 14.64% during the forecast period (2024 - 2032).
Key Advanced Therapy Medicinal Products CDMO Market Trends Highlighted
The Advanced Therapy Medicinal Products (ATMPs) CDMO market is seeing rapid growth, driven by the rising prevalence of chronic diseases and the increasing demand for personalized medicine.
Key market drivers include advancements in gene therapy, cell therapy, and tissue engineering, which are creating new opportunities for the development of ATMPs. Additionally, government initiatives and favorable regulatory environments are further fueling market growth.
Recent trends in the ATMP CDMO market include the adoption of innovative technologies such as artificial intelligence (AI) and machine learning (ML) to improve efficiency and precision in manufacturing processes.
The market is also witnessing a shift towards integrated CDMO services, where providers offer a comprehensive range of services from early-stage development to commercial manufacturing. Moreover, there is a growing focus on patient-centricity, with CDMOs prioritizing the delivery of high-quality, personalized therapies.
Opportunities for exploration in the ATMP CDMO market lie in the development of new ATMPs for unmet medical needs, the expansion into emerging markets, and the adoption of novel technologies. By leveraging these opportunities, CDMOs can position themselves for continued growth and success in this dynamic market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Advanced Therapy Medicinal Products CDMO Market Drivers
Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders, is a major driver of the global advanced therapy medicinal products CDMO market.
Advanced therapies, including gene therapies, cell therapies, and tissue engineering, offer promising treatment options for these debilitating conditions, leading to increased demand for CDMO services to support the development and manufacturing of these therapies.
The ability of advanced therapies to target specific genetic defects or disease mechanisms has opened up new avenues for personalized medicine, further fueling the growth of the CDMO market.
Moreover, the increasing prevalence of rare diseases for which traditional treatments may be ineffective is also contributing to the demand for advanced therapies and the associated CDMO services.
Technological Advancements and Innovation
The rapid pace of technological advancements in the field of biotechnology is another key driver of the global advanced therapy medicinal products CDMO market.
The development of novel gene editing techniques, such as CRISPR-Cas9, and advancements in cell culture and manufacturing technologies have significantly improved the efficiency and precision of advanced therapy development.
These technological advancements have enabled the creation of more effective and targeted therapies, leading to increased demand for CDMO services to support the scale-up and commercialization of these products.
Furthermore, ongoing research and development efforts in the field of regenerative medicine and tissue engineering hold immense promise for the treatment of a wide range of diseases and injuries, further driving the growth of the CDMO market.
Government Support and Regulatory Landscape
Government support and favorable regulatory policies play a crucial role in fostering the growth of the global advanced therapy medicinal products CDMO market. Governments worldwide recognize the potential of advanced therapies to transform healthcare and improve patient outcomes.
As a result, many countries have implemented supportive policies, including funding for research and development, tax incentives for companies investing in this field, and streamlined regulatory pathways for the approval of advanced therapies.
These measures have created a conducive environment for the development and commercialization of advanced therapies, leading to increased demand for CDMO services to support the manufacturing and clinical trials of these products.
Advanced Therapy Medicinal Products CDMO Market Segment Insights:
Advanced Therapy Medicinal Products CDMO Market Product Type Insights
The Advanced Therapy Medicinal Products CDMO Market is segmented by product type into gene therapy, cell therapy, and tissue engineering. Gene therapy involves modifying a patient's genes to treat or prevent a disease. Cell therapy involves using cells to repair or replace damaged tissues or organs.
Tissue engineering involves creating new tissues or organs from cells or other materials. The Advanced Therapy Medicinal Products CDMO Market revenue for gene therapy is expected to grow from USD 2.5 billion in 2023 to USD 10.5 billion by 2030, at a CAGR of 22.5%.
The growth of the gene therapy segment is attributed to the increasing prevalence of genetic disorders and the development of new gene therapies. The Advanced Therapy Medicinal Products CDMO Market revenue for cell therapy is expected to grow from USD 5.0 billion in 2023 to USD 20.0 billion by 2030, at a CAGR of 25.0%.
The growth of the cell therapy segment is attributed to the increasing demand for cell-based therapies for the treatment of cancer and other diseases. The Advanced Therapy Medicinal Products CDMO Market revenue for tissue engineering is expected to grow from USD 3.0 billion in 2023 to USD 12.0 billion by 2030, at a CAGR of 20.0%.
The growth of the tissue engineering segment is attributed to the increasing demand for tissue-engineered products for the repair and replacement of damaged tissues and organs.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Advanced Therapy Medicinal Products CDMO Market Indication Insights
The Advanced Therapy Medicinal Products CDMO Market is segmented by indication, which includes cancer, immune disorders, cardiovascular diseases, and neurological disorders. Among these, cancer holds the largest market share due to the increasing prevalence of various types of cancer and the growing demand for personalized and targeted therapies.
The Advanced Therapy Medicinal Products CDMO Market for Cancer is expected to reach USD 35.2 billion by 2024, growing at a CAGR of 15.2%. The market for immune disorders is also expected to witness significant growth, driven by the rising incidence of autoimmune diseases and the development of novel immunotherapies.
The cardiovascular diseases segment is expected to grow at a steady pace, supported by the increasing prevalence of cardiovascular diseases and the growing adoption of advanced therapies for the treatment of these diseases.
The neurological disorders segment is also expected to experience growth, driven by the increasing prevalence of neurological disorders and the growing demand for advanced therapies for the treatment of these disorders.
Advanced Therapy Medicinal Products CDMO Market Scale of Production Insights
The Scale of Production segment plays a crucial role in the global advanced therapy medicinal products CDMO market. It is categorized into two primary sub-segments: Clinical Trial and Commercial Production.
The Clinical Trial sub-segment held a significant share of the market in 2023, primarily driven by the increasing number of clinical trials for advanced therapies. As per market data, the Clinical Trial sub-segment is projected to reach a valuation of approximately 6.5 billion USD by 2032, exhibiting a robust CAGR of 13.2%.
The Commercial Production sub-segment is anticipated to witness substantial growth in the coming years, owing to the growing demand for commercial manufacturing of advanced therapies.
Industry statistics indicate that the Commercial Production sub-segment is expected to reach a valuation of around 5.8 billion USD by 2032, expanding at a CAGR of 14.9%.
This growth is attributed to the increasing prevalence of chronic diseases and the rising adoption of advanced therapies as treatment options.
Advanced Therapy Medicinal Products CDMO Market Service Type Insights
The Advanced Therapy Medicinal Products CDMO Market is segmented into service type, which includes process development, manufacturing, and regulatory support. The manufacturing segment is expected to hold the largest share of the market in 2023, with a valuation of 11.87 billion USD.
This is due to the increasing demand for contract manufacturing services for advanced therapy medicinal products (ATMPs) as companies look to outsource their manufacturing processes to specialized providers. The process development segment is expected to grow at the highest CAGR of 15.24% over the forecast period, as companies invest in developing new and innovative ATMPs.
Regulatory support is another important segment of the market, as companies require assistance in navigating the complex regulatory landscape for ATMPs.
Advanced Therapy Medicinal Products CDMO Market Regional Insights
The Advanced Therapy Medicinal Products CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period.
The growth of the North American market is attributed to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the presence of a large number of pharmaceutical and biotechnology companies in the region. Europe is expected to be the second-largest market for advanced therapy medicinal products CDMO in 2023 and is projected to grow at a steady pace during the forecast period.
The growth of the European market is attributed to the increasing healthcare expenditure, the rising demand for innovative therapies, and the presence of a number of leading pharmaceutical and biotechnology companies in the region.
The APAC market is expected to be the fastest-growing regional market for advanced therapy medicinal products CDMO during the forecast period. The growth of the APAC market is attributed to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the presence of a number of emerging pharmaceutical and biotechnology companies in the region.
South America and MEA are expected to be relatively smaller markets for advanced therapy medicinal products CDMO but are projected to grow at a steady pace during the forecast period.
The growth of these markets is attributed to the increasing healthcare expenditure, the rising demand for innovative therapies, and the presence of a number of emerging pharmaceutical and biotechnology companies in the region.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Advanced Therapy Medicinal Products CDMO Market Key Players and Competitive Insights:
Major players in the advanced therapy medicinal products CDMO market are focusing on developing innovative technologies and expanding their global presence through strategic partnerships and acquisitions.
Leading advanced therapy medicinal products CDMO market players are investing heavily in research and development to enhance their product portfolio and gain a competitive edge. The advanced therapy medicinal products CDMO market development is driven by rising demand for personalized medicine and increasing government support for regenerative therapies.
The competitive landscape is expected to remain fragmented, with several key players holding significant market share.
Lonza is a leading provider of Advanced Therapy Medicinal Products CDMO Market services, offering a comprehensive range of solutions for cell and gene therapies, including cell culture media, bioprocess development, and manufacturing.
The company has a strong global presence with facilities in Europe, North America, and Asia. Lonza's commitment to innovation and customer service has earned it a reputation as a trusted partner for biotechnology and pharmaceutical companies.
Samsung Biologics is another major player in the advanced therapy medicinal products CDMO market. The company offers a full suite of services for cell and gene therapy development and manufacturing, including cell line development, process optimization, and GMP manufacturing.
Samsung Biologics has a state-of-the-art manufacturing facility in South Korea and is expanding its global presence through partnerships with leading biotechnology companies.
Key Companies in the advanced therapy medicinal products CDMO market Include:
- MeiraGTx
- Wuxi Advanced Therapies
- Bristol-Myers Squibb
- Thermo Fisher Scientific
- Catalent
- Amgen
- Biogen
- AAV gene therapy
- Pfizer
- Fujifilm
- Samsung Biologics
- Cellectis
- Lonza
- Wuxi AppTec
Advanced Therapy Medicinal Products CDMO Market Developments
The global Advanced Therapy Medicinal Products (ATMPs) CDMO market is anticipated to witness significant growth in the coming years.
The growth is attributed to the increasing prevalence of chronic diseases, rising investments in ATMP research and development, and growing government support for regenerative medicine.
Recent developments include the expansion of ATMP manufacturing facilities, strategic partnerships between CDMOs and pharmaceutical companies, and the emergence of innovative technologies such as gene editing and cell therapy.
Key market players are focusing on providing end-to-end services, including process development, clinical trial manufacturing, and commercial-scale production.
Advanced Therapy Medicinal Products CDMO Market Segmentation Insights
- Advanced Therapy Medicinal Products CDMO Market Product Type Outlook
- Gene Therapy
- Cell Therapy
- Tissue Engineering
- Advanced Therapy Medicinal Products CDMO Market Indication Outlook
- Cancer
- Immune Disorders
- Cardiovascular Diseases
- Neurological Disorders
- Advanced Therapy Medicinal Products CDMO Market Scale of Production Outlook
- Clinical Trial
- Commercial Production
- Advanced Therapy Medicinal Products CDMO Market Service Type Outlook
- Process Development
- Manufacturing
- Regulatory Support
- Advanced Therapy Medicinal Products CDMO Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
19.89(USD Billion) |
| Market Size 2023 |
22.8(USD Billion) |
| Market Size 2032 |
78.0(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
14.64% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
MeiraGTx, WuXi Advanced Therapies, Bristol-Myers Squibb, Thermo Fisher Scientific, Catalent, Amgen, Biogen, AAV gene therapy, Pfizer, Fujifilm, Samsung Biologics, Cellectis, Lonza, Wuxi AppTec |
| Segments Covered |
Product Type, Indication, Scale of Production, Service Type, Regional |
| Key Market Opportunities |
Personalized treatments Gene editing advancements Expanding pipeline CAR Tcell therapies Targeted drug delivery |
| Key Market Dynamics |
Increased research and development investment Government initiatives Growing prevalence of chronic diseases Technological advancements Strategic collaborations |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Advanced Therapy Medicinal Products CDMO Market is expected to reach a valuation of USD 78.0 billion by 2032.
The Advanced Therapy Medicinal Products CDMO Market is projected to grow at a CAGR of 14.64% from 2024 to 2032.
North America is expected to hold the largest share of the Advanced Therapy Medicinal Products CDMO Market by 2032.
The cell therapy segment is expected to dominate the Advanced Therapy Medicinal Products CDMO Market by 2032.
Some of the key competitors in the Advanced Therapy Medicinal Products CDMO Market include Lonza, Thermo Fisher Scientific, and Catalent.
Factors such as the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in gene editing are driving the growth of the global advanced therapy medicinal products CDMO market.
Challenges such as regulatory hurdles, high production costs, and a shortage of skilled workforce are faced by the global advanced therapy medicinal products CDMO market.
Emerging technologies such as artificial intelligence and machine learning are expected to revolutionize the Advanced Therapy Medicinal Products CDMO Market by improving efficiency and reducing costs.
The Advanced Therapy Medicinal Products CDMO Market is expected to witness significant growth over the next 5 years, driven by factors such as the increasing demand for personalized medicine and the growing adoption of cell and gene therapies.
Key trends shaping the Advanced Therapy Medicinal Products CDMO Market include the increasing focus on patient-centricity, the rise of digital health technologies, and the growing importance of sustainability.
